Organization and Business - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended	65 Months Ended									6 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Sep. 30, 2012	Dec. 31, 2010	May 09, 2007	Sep. 30, 2012 Common Stock	Sep. 30, 2012 Private Placement memorandum	Sep. 30, 2012 Private Placement memorandum Common Stock Minimum	Jun. 30, 2012 Private Placement memorandum Common Stock Minimum	Sep. 30, 2012 Private Placement memorandum Common Stock Maximum	Jun. 30, 2012 Phase I clinical trial Person	Jun. 30, 2012 Phase I clinical trial Minimum Person	Jun. 30, 2012 Phase I clinical trial Maximum Person
Organization and Nature of Operations [Line Items]
Number of evaluable patients in Phase I Clinical trial													18	30
Number patients benefited from Liposomal Grb-2 treatment												3
Impairment of License	$ 345,000		$ 345,000	$ 690,000
Percentage of Charge			50.00%
Cash	$ 332,862	$ 983,286	$ 952,252	$ 332,862	$ 238,565		$ 795,001	$ 1,700,000	$ 2,000,000	$ 1,000,000	$ 4,000,000